Onglyza, Kombiglyze XR
(saxagliptin and saxagliptin/metformin)
Heart Failure, Pancreatic Cancer
Lawsuits allege that diabetic drugs Onglyza or Kombiglyze XR are linked to:
- congestive heart failure,
- heart attack,
- myocardial infarction,
- cardiovascular injury.
- pancreatic cancer
MDL 2809: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR Judicial Panel was created with over 200 cases consolidated in the Eastern District of Kentucky before the Honorable Karen Caldwell. The defendant manufacturers are Bristol-Myers Squibb and AstraZeneca.
Approved by the FDA in 2009, issues were highlighted when a panel of FDA advisors recommended that the drug’s manufacturers update the products label to include the potential risk of heart failure. Results from a clinical trial entitled, SAVOR-TIMI 53 clinical trial (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with Diabetes Mellitus) was published in the New England Journal of Medicine.
However, the FDA did not order Bristol-Myers Squibb and AstraZeneca to modify the products’ “Warnings and Precautions” labels until years later in 2016. In 2017, consolidation of all the Onglyza and Kombiglyze XR lawsuits was requested and eventually centralized in the Eastern District of Kentucky in February 2018. California residents claiming Onglyza caused heart failure are filed in state superior court before Judge Curtis E.A. Karnow as Case No. CJC-16-004909.
Healthcare professionals should counsel patients regarding symptoms of heart failure and observe patients for signs and symptoms of heart failure, including:
- Swollen ankles, feet, legs, or stomach
- Feeling tired, weak, or fatigued
- Shortness of breath
- Difficult breathing when lying down
If you have suffered heart failure after taking Onglyza or Kombiglyze XR, Contact Us for a free medical legal consultation.